Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer

A need exists for seeking effective treatments for castration-resistant prostate cancer (CRPC) in response to its emergence following androgen deprivation therapy as a major clinical problem. In the present study, we investigated the chemopreventive and chemotherapeutic potential of luteolin, a flav...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Carcinogenesis (New York) 2020-08, Vol.41 (8), p.1145-1157
Hauptverfasser: Naiki-Ito, Aya, Naiki, Taku, Kato, Hiroyuki, Iida, Keitaro, Etani, Toshiki, Nagayasu, Yuko, Suzuki, Shugo, Yamashita, Yoriko, Inaguma, Shingo, Onishi, Masaya, Tanaka, Yasuhito, Yasui, Takahiro, Takahashi, Satoru
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1157
container_issue 8
container_start_page 1145
container_title Carcinogenesis (New York)
container_volume 41
creator Naiki-Ito, Aya
Naiki, Taku
Kato, Hiroyuki
Iida, Keitaro
Etani, Toshiki
Nagayasu, Yuko
Suzuki, Shugo
Yamashita, Yoriko
Inaguma, Shingo
Onishi, Masaya
Tanaka, Yasuhito
Yasui, Takahiro
Takahashi, Satoru
description A need exists for seeking effective treatments for castration-resistant prostate cancer (CRPC) in response to its emergence following androgen deprivation therapy as a major clinical problem. In the present study, we investigated the chemopreventive and chemotherapeutic potential of luteolin, a flavonoid with antioxidative properties, on prostate cancer, including CRPC. Luteolin inhibited the progression of rat prostate carcinogenesis by induction of apoptosis in a transgenic rat for adenocarcinoma of prostate (TRAP) model. Luteolin decreased cell proliferation in a dose-dependent manner and induced apoptosis with the activation of caspases 3 and 7 in both rat (PCai1, established from a TRAP prostate tumor) and human (22Rv1) CRPC cells. Dietary luteolin also suppressed tumor growth via an increase in apoptosis and inhibition of angiogenesis in PCai1 and 22Rv1 xenografts implanted in castrated nude mice. We also focused on androgen receptor splice variant 7 (AR-V7), which contributes to cell proliferation and therapeutic resistance in CRPC. Luteolin dramatically suppressed AR-V7 protein expression in 22Rv1 cells in vitro and ex vivo. Microarray analysis identified MiR-8080, which contains a possible target sequence for AR-V7 3'-UTR, as a gene upregulated by luteolin. MiR-8080 transfection decreased the AR-V7 expression level and the induction of apoptosis in 22Rv1 cells. Furthermore, miR-8080 knockdown canceled luteolin decreasing AR-V7 and the cell growth of 22Rv1. MiR-8080 induced by luteolin intake enhanced the therapeutic effect of enzalutamide on 22Rv1 xenografts under castration conditions. These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.
doi_str_mv 10.1093/carcin/bgz193
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7422625</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31805186</sourcerecordid><originalsourceid>FETCH-LOGICAL-c383t-256ba3726c5a4132ae5c6faff26328810d1774248dfe6b938b8944d719eab3bb3</originalsourceid><addsrcrecordid>eNpVkU1LxDAQhoMo7vpx9Cr5A9Uk06bpRZDFL1gQFj2XJJ2ukW5bkqy4Hv3lZlkVPWWS950nzLyEnHF2wVkFl1Z76_pLs_zgFeyRKc8lywRXbJ9MGc8hA4B8Qo5CeGWMSyiqQzKBpBdcySn5XKD1axdX2Ec6tHTlFpliilGzod064tC5nrr-xRkXA9V944cl9tSjxTEOnoaxcxbpm_ZOJ0JJ8X30GIIbtm3U6hC9jumWpVcX4tY0-iEVEZPaW_Qn5KDVXcDT7_OYPN_ePM3us_nj3cPsep5ZUBAzUUijoRTSFjrnIDQWVra6bYUEoRRnDS_LXOSqaVGaCpRRVZ43Ja9QGzAGjsnVjjuuzQobmyb2uqtH71bab-pBu_q_0ruXejm81YkqpCgSINsBbBogeGx_ezmrt2HUuzDqXRjJf_73w1_3z_bhC6zxi94</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer</title><source>AUTh Library subscriptions: Oxford University Press</source><source>Free E-Journal (出版社公開部分のみ)</source><source>Alma/SFX Local Collection</source><creator>Naiki-Ito, Aya ; Naiki, Taku ; Kato, Hiroyuki ; Iida, Keitaro ; Etani, Toshiki ; Nagayasu, Yuko ; Suzuki, Shugo ; Yamashita, Yoriko ; Inaguma, Shingo ; Onishi, Masaya ; Tanaka, Yasuhito ; Yasui, Takahiro ; Takahashi, Satoru</creator><creatorcontrib>Naiki-Ito, Aya ; Naiki, Taku ; Kato, Hiroyuki ; Iida, Keitaro ; Etani, Toshiki ; Nagayasu, Yuko ; Suzuki, Shugo ; Yamashita, Yoriko ; Inaguma, Shingo ; Onishi, Masaya ; Tanaka, Yasuhito ; Yasui, Takahiro ; Takahashi, Satoru</creatorcontrib><description>A need exists for seeking effective treatments for castration-resistant prostate cancer (CRPC) in response to its emergence following androgen deprivation therapy as a major clinical problem. In the present study, we investigated the chemopreventive and chemotherapeutic potential of luteolin, a flavonoid with antioxidative properties, on prostate cancer, including CRPC. Luteolin inhibited the progression of rat prostate carcinogenesis by induction of apoptosis in a transgenic rat for adenocarcinoma of prostate (TRAP) model. Luteolin decreased cell proliferation in a dose-dependent manner and induced apoptosis with the activation of caspases 3 and 7 in both rat (PCai1, established from a TRAP prostate tumor) and human (22Rv1) CRPC cells. Dietary luteolin also suppressed tumor growth via an increase in apoptosis and inhibition of angiogenesis in PCai1 and 22Rv1 xenografts implanted in castrated nude mice. We also focused on androgen receptor splice variant 7 (AR-V7), which contributes to cell proliferation and therapeutic resistance in CRPC. Luteolin dramatically suppressed AR-V7 protein expression in 22Rv1 cells in vitro and ex vivo. Microarray analysis identified MiR-8080, which contains a possible target sequence for AR-V7 3'-UTR, as a gene upregulated by luteolin. MiR-8080 transfection decreased the AR-V7 expression level and the induction of apoptosis in 22Rv1 cells. Furthermore, miR-8080 knockdown canceled luteolin decreasing AR-V7 and the cell growth of 22Rv1. MiR-8080 induced by luteolin intake enhanced the therapeutic effect of enzalutamide on 22Rv1 xenografts under castration conditions. These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.</description><identifier>ISSN: 0143-3334</identifier><identifier>EISSN: 1460-2180</identifier><identifier>DOI: 10.1093/carcin/bgz193</identifier><identifier>PMID: 31805186</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Carcinogenesis</subject><ispartof>Carcinogenesis (New York), 2020-08, Vol.41 (8), p.1145-1157</ispartof><rights>The Author(s) 2019. Published by Oxford University Press.</rights><rights>The Author(s) 2019. Published by Oxford University Press. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c383t-256ba3726c5a4132ae5c6faff26328810d1774248dfe6b938b8944d719eab3bb3</citedby><cites>FETCH-LOGICAL-c383t-256ba3726c5a4132ae5c6faff26328810d1774248dfe6b938b8944d719eab3bb3</cites><orcidid>0000-0003-0828-2033</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31805186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Naiki-Ito, Aya</creatorcontrib><creatorcontrib>Naiki, Taku</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><creatorcontrib>Iida, Keitaro</creatorcontrib><creatorcontrib>Etani, Toshiki</creatorcontrib><creatorcontrib>Nagayasu, Yuko</creatorcontrib><creatorcontrib>Suzuki, Shugo</creatorcontrib><creatorcontrib>Yamashita, Yoriko</creatorcontrib><creatorcontrib>Inaguma, Shingo</creatorcontrib><creatorcontrib>Onishi, Masaya</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><creatorcontrib>Yasui, Takahiro</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><title>Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer</title><title>Carcinogenesis (New York)</title><addtitle>Carcinogenesis</addtitle><description>A need exists for seeking effective treatments for castration-resistant prostate cancer (CRPC) in response to its emergence following androgen deprivation therapy as a major clinical problem. In the present study, we investigated the chemopreventive and chemotherapeutic potential of luteolin, a flavonoid with antioxidative properties, on prostate cancer, including CRPC. Luteolin inhibited the progression of rat prostate carcinogenesis by induction of apoptosis in a transgenic rat for adenocarcinoma of prostate (TRAP) model. Luteolin decreased cell proliferation in a dose-dependent manner and induced apoptosis with the activation of caspases 3 and 7 in both rat (PCai1, established from a TRAP prostate tumor) and human (22Rv1) CRPC cells. Dietary luteolin also suppressed tumor growth via an increase in apoptosis and inhibition of angiogenesis in PCai1 and 22Rv1 xenografts implanted in castrated nude mice. We also focused on androgen receptor splice variant 7 (AR-V7), which contributes to cell proliferation and therapeutic resistance in CRPC. Luteolin dramatically suppressed AR-V7 protein expression in 22Rv1 cells in vitro and ex vivo. Microarray analysis identified MiR-8080, which contains a possible target sequence for AR-V7 3'-UTR, as a gene upregulated by luteolin. MiR-8080 transfection decreased the AR-V7 expression level and the induction of apoptosis in 22Rv1 cells. Furthermore, miR-8080 knockdown canceled luteolin decreasing AR-V7 and the cell growth of 22Rv1. MiR-8080 induced by luteolin intake enhanced the therapeutic effect of enzalutamide on 22Rv1 xenografts under castration conditions. These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.</description><subject>Carcinogenesis</subject><issn>0143-3334</issn><issn>1460-2180</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LxDAQhoMo7vpx9Cr5A9Uk06bpRZDFL1gQFj2XJJ2ukW5bkqy4Hv3lZlkVPWWS950nzLyEnHF2wVkFl1Z76_pLs_zgFeyRKc8lywRXbJ9MGc8hA4B8Qo5CeGWMSyiqQzKBpBdcySn5XKD1axdX2Ec6tHTlFpliilGzod064tC5nrr-xRkXA9V944cl9tSjxTEOnoaxcxbpm_ZOJ0JJ8X30GIIbtm3U6hC9jumWpVcX4tY0-iEVEZPaW_Qn5KDVXcDT7_OYPN_ePM3us_nj3cPsep5ZUBAzUUijoRTSFjrnIDQWVra6bYUEoRRnDS_LXOSqaVGaCpRRVZ43Ja9QGzAGjsnVjjuuzQobmyb2uqtH71bab-pBu_q_0ruXejm81YkqpCgSINsBbBogeGx_ezmrt2HUuzDqXRjJf_73w1_3z_bhC6zxi94</recordid><startdate>20200812</startdate><enddate>20200812</enddate><creator>Naiki-Ito, Aya</creator><creator>Naiki, Taku</creator><creator>Kato, Hiroyuki</creator><creator>Iida, Keitaro</creator><creator>Etani, Toshiki</creator><creator>Nagayasu, Yuko</creator><creator>Suzuki, Shugo</creator><creator>Yamashita, Yoriko</creator><creator>Inaguma, Shingo</creator><creator>Onishi, Masaya</creator><creator>Tanaka, Yasuhito</creator><creator>Yasui, Takahiro</creator><creator>Takahashi, Satoru</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0828-2033</orcidid></search><sort><creationdate>20200812</creationdate><title>Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer</title><author>Naiki-Ito, Aya ; Naiki, Taku ; Kato, Hiroyuki ; Iida, Keitaro ; Etani, Toshiki ; Nagayasu, Yuko ; Suzuki, Shugo ; Yamashita, Yoriko ; Inaguma, Shingo ; Onishi, Masaya ; Tanaka, Yasuhito ; Yasui, Takahiro ; Takahashi, Satoru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c383t-256ba3726c5a4132ae5c6faff26328810d1774248dfe6b938b8944d719eab3bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Carcinogenesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Naiki-Ito, Aya</creatorcontrib><creatorcontrib>Naiki, Taku</creatorcontrib><creatorcontrib>Kato, Hiroyuki</creatorcontrib><creatorcontrib>Iida, Keitaro</creatorcontrib><creatorcontrib>Etani, Toshiki</creatorcontrib><creatorcontrib>Nagayasu, Yuko</creatorcontrib><creatorcontrib>Suzuki, Shugo</creatorcontrib><creatorcontrib>Yamashita, Yoriko</creatorcontrib><creatorcontrib>Inaguma, Shingo</creatorcontrib><creatorcontrib>Onishi, Masaya</creatorcontrib><creatorcontrib>Tanaka, Yasuhito</creatorcontrib><creatorcontrib>Yasui, Takahiro</creatorcontrib><creatorcontrib>Takahashi, Satoru</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Carcinogenesis (New York)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Naiki-Ito, Aya</au><au>Naiki, Taku</au><au>Kato, Hiroyuki</au><au>Iida, Keitaro</au><au>Etani, Toshiki</au><au>Nagayasu, Yuko</au><au>Suzuki, Shugo</au><au>Yamashita, Yoriko</au><au>Inaguma, Shingo</au><au>Onishi, Masaya</au><au>Tanaka, Yasuhito</au><au>Yasui, Takahiro</au><au>Takahashi, Satoru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer</atitle><jtitle>Carcinogenesis (New York)</jtitle><addtitle>Carcinogenesis</addtitle><date>2020-08-12</date><risdate>2020</risdate><volume>41</volume><issue>8</issue><spage>1145</spage><epage>1157</epage><pages>1145-1157</pages><issn>0143-3334</issn><eissn>1460-2180</eissn><abstract>A need exists for seeking effective treatments for castration-resistant prostate cancer (CRPC) in response to its emergence following androgen deprivation therapy as a major clinical problem. In the present study, we investigated the chemopreventive and chemotherapeutic potential of luteolin, a flavonoid with antioxidative properties, on prostate cancer, including CRPC. Luteolin inhibited the progression of rat prostate carcinogenesis by induction of apoptosis in a transgenic rat for adenocarcinoma of prostate (TRAP) model. Luteolin decreased cell proliferation in a dose-dependent manner and induced apoptosis with the activation of caspases 3 and 7 in both rat (PCai1, established from a TRAP prostate tumor) and human (22Rv1) CRPC cells. Dietary luteolin also suppressed tumor growth via an increase in apoptosis and inhibition of angiogenesis in PCai1 and 22Rv1 xenografts implanted in castrated nude mice. We also focused on androgen receptor splice variant 7 (AR-V7), which contributes to cell proliferation and therapeutic resistance in CRPC. Luteolin dramatically suppressed AR-V7 protein expression in 22Rv1 cells in vitro and ex vivo. Microarray analysis identified MiR-8080, which contains a possible target sequence for AR-V7 3'-UTR, as a gene upregulated by luteolin. MiR-8080 transfection decreased the AR-V7 expression level and the induction of apoptosis in 22Rv1 cells. Furthermore, miR-8080 knockdown canceled luteolin decreasing AR-V7 and the cell growth of 22Rv1. MiR-8080 induced by luteolin intake enhanced the therapeutic effect of enzalutamide on 22Rv1 xenografts under castration conditions. These results indicate luteolin inhibits CRPC by AR-V7 suppression through miR-8080, highlighting luteolin and miR-8080 as promising therapeutic agents for this disease.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>31805186</pmid><doi>10.1093/carcin/bgz193</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0003-0828-2033</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0143-3334
ispartof Carcinogenesis (New York), 2020-08, Vol.41 (8), p.1145-1157
issn 0143-3334
1460-2180
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7422625
source AUTh Library subscriptions: Oxford University Press; Free E-Journal (出版社公開部分のみ); Alma/SFX Local Collection
subjects Carcinogenesis
title Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A20%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recruitment%20of%20miR-8080%20by%20luteolin%20inhibits%20androgen%20receptor%20splice%20variant%207%20expression%20in%20castration-resistant%20prostate%20cancer&rft.jtitle=Carcinogenesis%20(New%20York)&rft.au=Naiki-Ito,%20Aya&rft.date=2020-08-12&rft.volume=41&rft.issue=8&rft.spage=1145&rft.epage=1157&rft.pages=1145-1157&rft.issn=0143-3334&rft.eissn=1460-2180&rft_id=info:doi/10.1093/carcin/bgz193&rft_dat=%3Cpubmed_cross%3E31805186%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31805186&rfr_iscdi=true